Officially designated as a member of the Marathon of Hope Cancer Centres Network (MOHCCN) in December 2022, the Atlantic Cancer Consortium (ACC) shares the MOHCCN vision to unite Canada to cure cancer. We are aligned with the MOHCCN mission to create a national network that applies world-leading science to cancer care, with a focus on precision medicine. We have rallied our region’s leading cancer researchers, institutions and care facilities to unite around this vision to enhance inter-institutional and inter-provincial cancer research collaboration, to increase cancer research capacity and productivity and to train the next generation of ACC cancer researchers in precision medicine.
As the smallest region joining the MOHCCN, Atlantic Canada has always taken a regionally collaborative approach to cancer research. Assembling our collective critical mass has been essential to creating a thriving cancer research environment. With the
MOHCCN, the ACC is excited to contribute to the advancement of cancer research nationally through the engagement with rural and underserved communities to deliver precision oncology opportunities, engagement with Indigenous communities to develop
a framework for collaboration, and the implementation of precision medicine in the clinical setting, immunology, metabolism, and biomarkers.
Partners
- Atlantic Cancer Research Institute
- Dalhousie University
- Eastern Health
- Horizon Health
- Memorial University of Newfoundland
- Nova Scotia Health
- University of Prince Edward Island
- Vitalité Health Network
Projects
| Projects | Project leads |
|
| TFRI Atlantic Canada Myeloma Cohort | Manal Elnenaei, Tony Reiman |
| Deciphering (epi)genetics interplay in colorectal cancer | Touati Benoukraf, Sevtap Savas |
| Investigating Serial plasma extracellular vesicle Genomics in High-Grade astrocytoma Tumors (IN-SIGHT) | Jeremy Roy, Adrienne Weeks |
| Liquid biopsy for the detection of drug-targetable mutation in lung cancer patients | Zhaolin Xu, Michael Carter |
| Genetic and environmental factors driving hematologic cancer rates in Atlantic Canada | Amy Trottier, Graham Dellaire |
| Genetic and Environmental factors driving Lung Cancer Rates in Atlantic Canada | Graham Dellaire, Alison Wallace, Victor Martinez |
| High parameter spatial biology for assessment of immune contexture | Dirk Arnold, Jeanette Boudreau, Sidney Croul, Dan Gaston |
| Defining the Prevalence and Function of the Serine Biosynthesis Pathway Across Breast Cancer Molecular Subtypes | Patrick Murphy and Marya Ahmed |
| Identification of Novel Targets in Primary and Metastatic Breast Cancers | Marya Ahmed |
| Profiling the coding and long non-coding transcriptome to identify novel genetic mediators of breast tumor immune suppression | Paola Marcato, Gregory Knapp, Gillian Bethune, Tobias Karakach |
| Pan-cancer extracellular vesicle (EV) liquid biopsy signatures as predictors of response to immune checkpoint inhibitors | Rodney J Ouellette, Jeanette Boudreau, Catherine Taylor, Michael Ha, Alexi Surette, Nicholas Finn, Mahmoud Abdelsalam |
| The use of extracellular vesicles to improve breast cancer screening and monitoring | Sherri Christian |
| Oncometabolomics Profiling Program | Pinto, El Hiani, Marcato, Murphy, Karakach, Brunt, Kienesberger, Brown, Xu, Reiman, Gujar and Pulinilkunnil |
